ASCO Meeting Features First Independent Comparison of Breast Cancer Genomic Tests

The combined MammaPrint and BluePrint genomic tests provide more information about the specifics of breast cancer than does the older, 21-gene test, according to the first independent assessment comparing the assays. That study was among the major new findings about breast cancer molecular diagnostics – also called genomic tests – emerging from this year’s recent annual meeting of the American Society of Clinical Oncology (ASCO).

Brufsky for DD blogAlso featured at ASCO were new insights about breast cancer in African-American women, drawn from research with MammaPrint and BluePrint conducted in the nation’s capital.

Together, the 70-gene MammaPrint and 80-gene BluePrint tests definitively categorize patients as Low Risk or High Risk for breast cancer recurrence and provide additional information about the specific biology of the cancer. The older and less sophisticated 21-gene test, on the other hand, stratifies patients into three risk-recurrence categories: Low Risk, High Risk, and Intermediate. Continue reading “ASCO Meeting Features First Independent Comparison of Breast Cancer Genomic Tests”